Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis

References

• ReginsterJYBurletNOsteoporosis: a still increasing prevalenceBone2006382 Suppl 1S4S916455317
   PubMed Web of Science ®Google Scholar
• RotellaDPOsteoporosis: challenges and new opportunities for therapyCurr Opin Drug Discov Devel200254477486
   Google Scholar
• BonuraFPrevention, screening, and management of osteoporosis: an overview of the current strategiesPostgrad Med2009121451719641263
   PubMed Web of Science ®Google Scholar
• WHOPrevention and management of osteoporosisWorld Health Organ Tech Rep Ser2003921116415293701
   PubMed Web of Science ®Google Scholar
• KanisJAOdenAJohnellOThe use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and womenOsteoporos Int200781033104617323110
   PubMed Web of Science ®Google Scholar
• KanisJFRAXTM WHO fracture risk assessment toolhttp://wwwshe-facuk/FRAX/indexhtm Accessed September15, 2009.
   Google Scholar
• BonnickSLShulmanLMonitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?Am J Med20061194 Suppl 1S25S3116563938
   PubMed Web of Science ®Google Scholar
• CurtisJRWestfallAOChengHDelzellESaagKGRisk of hip fracture after bisphosphonate discontinuation: implications for a drug holidayOsteoporos Int200819111613162018483689
   PubMed Web of Science ®Google Scholar
• EastellRTreatment of postmenopausal osteoporosisN Engl J Med1998338117367469494151
   PubMed Web of Science ®Google Scholar
• BarrettJWorthEBaussFEpsteinSIbandronate: a clinical pharmacological and pharmacokinetic updateJ Clin Pharmacol200444995196515317823
   PubMed Web of Science ®Google Scholar
• WaknineYZoledronic acid injection approved to prevent postmenopausal osteoporosis2009Available from: http://www.medscape.com/viewarticle/703898 Accessed December 31, 2009.
   Google Scholar
• FDA Approves Zometa (Zoledronic Acid) for Hypercalcemia of MalignancyAvailable at: http://www.docguide.com/news/content.nsf/news/00EF3B1D01A2414585256AAF004B4646 Accessed May 26, 2010.
   Google Scholar
• LiECDavisLEZoledronic acid: a new parenteral bisphosphonateClin Ther200325112669270814693298
   PubMed Web of Science ®Google Scholar
• KeatingGMScottLJZoledronic acid: a review of its use in the treatment of Paget’s disease of boneDrugs200767579380417385948
   PubMed Web of Science ®Google Scholar
• DeeksEDPerryCMZoledronic acid: a review of its use in the treatment of osteoporosisDrugs Aging2008251196398618947264
   PubMed Web of Science ®Google Scholar
• WellingtonKGoaKLZoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancyDrugs200363441743712558465
   PubMed Web of Science ®Google Scholar
• RingeJZoledronic acid in the treatment of Paget’s disease and other benign bone disordersExpert Rev Endocrinol Metab2006111524
   PubMedGoogle Scholar
• RussellRGBisphosphonates: from bench to bedsideAnn N Y Acad Sci2006106836740116831938
   PubMed Web of Science ®Google Scholar
• NancollasGHTangRPhippsRJNovel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatiteBone200638561762716046206
   PubMed Web of Science ®Google Scholar
• CoxonFPHelfrichMHVan’t HofRProtein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298J Bone Miner Res20001581467147610934645
   PubMed Web of Science ®Google Scholar
• FromigueOBodyJJBisphosphonates influence the proliferation and the maturation of normal human osteoblastsJ Endocrinol Invest200225653954612109626
   PubMed Web of Science ®Google Scholar
• von KnochFJaquieryCKowalskyMEffects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cellsBiomaterials200526346941694916009417
   PubMed Web of Science ®Google Scholar
• KavanaghKLGuoKDunfordJEThe molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugsProc Natl Acad Sci U S A2006103207829783416684881
   PubMed Web of Science ®Google Scholar
• DunfordJEThompsonKCoxonFPStructure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonatesJ Pharmacol Exp Ther2001296223524211160603
   PubMed Web of Science ®Google Scholar
• ReidIRBrownJPBurckhardtPIntravenous zoledronic acid in postmenopausal women with low bone mineral densityN Engl J Med2002346965366111870242
   PubMed Web of Science ®Google Scholar
• DevogelaerJPBrownJPBurckhardtPZoledronic acid efficacy and safety over five years in postmenopausal osteoporosisOsteoporos Int20071891211121817516022
   PubMed Web of Science ®Google Scholar
• ReckerRStakkestadJAChesnutCHInsufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosisBone200434589089915121021
   PubMed Web of Science ®Google Scholar
• BlackDMDelmasPDEastellROnce-yearly zoledronic acid for treatment of postmenopausal osteoporosisN Engl J Med2007356181809182217476007
   PubMed Web of Science ®Google Scholar
• HarrisSTWattsNBGenantHKEffects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study GroupJama1999282141344135210527181
   PubMed Web of Science ®Google Scholar
• ReginsterJMinneHWSorensenOHRandomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupOsteoporos Int2000111839110663363
   PubMed Web of Science ®Google Scholar
• ChesnutICSkagAChristiansenCEffects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosisJ Bone Miner Res20041981241124915231010
   PubMed Web of Science ®Google Scholar
• SirisEAdachiJDLuYEffects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene EvaluationOsteoporos Int2002131190791312415439
   PubMed Web of Science ®Google Scholar
• BlackDMCummingsSRKarpfDBRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research GroupLancet19963489041153515418950879
   PubMed Web of Science ®Google Scholar
• MillerPDMcClungMRMacoveiLMonthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE studyJ Bone Miner Res20052081315132216007327
   PubMed Web of Science ®Google Scholar
• ReginsterJYWilsonKMDumontEBonvoisinBBarrettJMonthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot studyJ Clin Endocrinol Metab20059095018502415972582
   PubMed Web of Science ®Google Scholar
• ReckerRRDelmasPDHalseJEffects of intravenous zoledronic acid once yearly on bone remodeling and bone structureJ Bone Miner Res200823161617892374
   PubMed Web of Science ®Google Scholar
• McClungMReckerRMillerPIntravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronateBone200741112212817468062
   PubMed Web of Science ®Google Scholar
• SaagKLindsayRKriegmanABeamerEZhouWA single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral densityBone20074051238124317347063
   PubMed Web of Science ®Google Scholar
• McClungMMillerPRecknorCMesenbrinkPBucci-RechtwegCBenhamouCLZoledronic acid for the prevention of bone loss in postmenopausal women with low bone massObstet Gynecol2009114519
   Web of Science ®Google Scholar
• GreyABollandMJWattieDHorneAGambleGReidIRThe anti-resorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal womenJ Clin Endocrinol Metab200994253854419050050
   PubMed Web of Science ®Google Scholar
• BoonenSAutierPBaretteMVanderschuerenDLipsPHaentjensPFunctional outcome and quality of life following hip fracture in elderly women: a prospective controlled studyOsteoporos Int2004152879414605799
   PubMed Web of Science ®Google Scholar
• Colon-EmericCKuchibhatlaMPieperCThe contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studiesOsteoporos Int2003141187988314530910
   PubMed Web of Science ®Google Scholar
• LylesKWColon-EmericCSMagazinerJSZoledronic acid and clinical fractures and mortality after hip fractureN Engl J Med20073571799180917878149
   PubMed Web of Science ®Google Scholar
• EriksenEFLylesKWColon-EmericCSAntifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fractureJ Bone Miner Res20092471308131319257818
   PubMed Web of Science ®Google Scholar
• HaneyEMBliziotesMMMale osteoporosis: new insights in an understudied diseaseCurr Opin Rheumatol200820442342818525355
   PubMed Web of Science ®Google Scholar
• BoonenSMagazinerJLylesKWEffect of once-yearly i.v. zoledronic acid in men after hip fracture: results from the horizon-recurrent fracture trial [abstract no. P251]Osteoporos Int200920Suppl 1S23S176
   Google Scholar
• Colon-EmericCSMesenbrinkPLylesKWPotential mediators of the mortality reduction with zoledronic acid after hip fractureJ Bone Miner Res2009251919719580467
   PubMed Web of Science ®Google Scholar
• OrwollEMillerPAdachiJOnce-yearly i.v. zoledronic acid 5 mg versus weekly oral alendronate 70 mg in men with osteoporosisENDO 2009Abstracts2View OnlineAbstract OR13-3. Chevy Chase, MDThe Endocrine Society2009http://www.endo-society.org/endo09/ Accessed February 1, 2010.
   Google Scholar
• LetochaADCintasHLTroendleJFControlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvementJ Bone Miner Res200520697798615883638
   PubMed Web of Science ®Google Scholar
• DimeglioLAFordLMcClintockCPeacockMA comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfectaJ Pediatr Endocrinol Metab2005181435315679068
   PubMed Web of Science ®Google Scholar
• SeikalyMGKopanatiSSalhabNImpact of alendronate on quality of life in children with osteogenesis imperfectaJ Pediatr Orthop200525678679116294137
   PubMed Web of Science ®Google Scholar
• BrownJJZacharinMRSafety and efficacy of intravenous zoledronic acid in paediatric osteoporosisJ Pediatr Endocrinol Metab2009221556319344075
   PubMed Web of Science ®Google Scholar
• BoonenSBlackDMColón-EmericCSEfficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly osteoporotic postmenopausal women aged 75 years and olderJ Am Geriatr Soc201058229229920070415
   PubMed Web of Science ®Google Scholar
• Van StaaTPLeufkensHGAbenhaimLZhangBCooperCOral corticosteroids and fracture risk: relationship to daily and cumulative dosesRheumatology (Oxford)200039121383138911136882
   PubMed Web of Science ®Google Scholar
• Van StaaTPLeufkensHGAbenhaimLZhangBCooperCUse of oral corticosteroids and risk of fracturesJ Bone Miner Res2000156993100010841167
   PubMed Web of Science ®Google Scholar
• Van StaaTPLeufkensHGCooperCThe epidemiology of corticosteroid-induced osteoporosis: a meta-analysisOsteoporos Int2002131077778712378366
   PubMed Web of Science ®Google Scholar
• DevogelaerJPGoemaereSBoonenSEvidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone ClubOsteoporos Int200617181916217586
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced OsteoporosisRecommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced OsteoporosisArthritis Rheum20014471496150311465699
   PubMed Web of Science ®Google Scholar
• ReidDMDevogelaerJPSaagKZoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trialLancet200937396711253126319362675
   PubMed Web of Science ®Google Scholar
• OtrockZKAzarSTShamseddeenWAIntravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trialAnn Hematol200685960560916830143
   PubMed Web of Science ®Google Scholar
• OtrockZKMahfouzRACharafeddineKMRayesRFZahedLFTaherATVitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosisAnn Hematol2008871194794818443790
   PubMed Web of Science ®Google Scholar
• VoskaridouEAnagnostopoulosAKonstantopoulosKZoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trialHaematologica20069191193120216956818
   PubMed Web of Science ®Google Scholar
• VoskaridouEChristoulasDKonstantinidouMTsiftsakisEAlexakosPTerposEContinuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trialHaematologica200893101588159018698086
   PubMed Web of Science ®Google Scholar
• RingeJDFarahmandPDorstAIntravenous zoledronic acid: a rapid and very effective treatment in localized transient osteoporosis of the hipOsteologie20071628
   Google Scholar
• ReidIRMillerPLylesKComparison of a single infusion of zoledronic acid with risedronate for Paget’s diseaseN Engl J Med2005353989890816135834
   PubMed Web of Science ®Google Scholar
• HoskingDLylesKBrownJPLong-term control of bone turnover in Paget’s disease with zoledronic acid and risedronateJ Bone Miner Res200722114214817032148
   PubMed Web of Science ®Google Scholar
• MercadanteSMalignant bone pain: pathophysiology and treatmentPain1997691–21189060007
   PubMed Web of Science ®Google Scholar
• SaadFGleasonDMMurrayRA randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinomaJ Natl Cancer Inst200294191458146812359855
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDKaminskiMZoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trialCancer J20017537738711693896
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDKaminskiMLong-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trialCancer20039881735174414534891
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDTchekmedyianSZoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial – the Zoledronic Acid Lung Cancer and Other Solid Tumors Study GroupJ Clin Oncol200321163150315712915606
   PubMed Web of Science ®Google Scholar
• BhoopalamNCampbellSCMoritzTIntravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapyJ Urol200918252257226419758618
   PubMed Web of Science ®Google Scholar
• Zoledronic acid in prevention of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal womenAHFS Drug Information^® Off-label Use Determinations2008Available from: http://www.ahfsdruginformation.com/off_label/tables/Zoledronic_Acid.pdf Accessed May 26, 2010.
   Google Scholar
• DemontieroODuqueGOnce-yearly zoledronic acid in hip fracture preventionClin Interv Aging20094115316419503777
   PubMed Web of Science ®Google Scholar
• GrbicJTLandesbergRLinSQIncidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trialJ Am Dent Assoc20081391324018167382
   PubMed Web of Science ®Google Scholar
• ReginsterJYRabendaVPatient preference in the management of postmenopausal osteoporosis with bisphosphonatesClin Interv Aging20061441542318046918
   PubMed Web of Science ®Google Scholar
• EastellRGarneroPVrijensBInfluence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT studyCalcif Tissue Int200372408
   Google Scholar
• SebaldtRJShaneLPhamBLonger-term effectiveness outcomes of non-compliance and non-persistence with daily-regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist careOsteoporos Int200415Suppl 1S107
   Google Scholar
• CaroJJIshakKJHuybrechtsKFRaggioGNaujoksCThe impact of compliance with osteoporosis therapy on fracture rates in actual practiceOsteoporos Int200415121003100815167989
   PubMed Web of Science ®Google Scholar
• HarrisSTSirisEAbbottTBarrCEHarrisSRosenCReduced osteoporotic fracture risk in patients adherence to bisphosphonate therapyProgram and Abstracts of The Endocrine Society’s 87th Annual Meeting2005 June 4–720053382
   Google Scholar
• SirisEHarrisSSilvermanSAbbottTBarrCRosenCAdherence to bisphosphonates (BPs) is associated with reduced fracture risk in women with postmenopausal osteoporosis (PMO)Menopause200512807
   Web of Science ®Google Scholar
• CummingsSRBlackDMThompsonDEEffect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention TrialJama199828024207720829875874
   PubMed Web of Science ®Google Scholar
• BoneHGAdamiSRizzoliRWeekly administration of alendronate: rationale and plan for clinical assessmentClin Ther2000221152810688387
   PubMed Web of Science ®Google Scholar
• SchnitzerTBoneHGCrepaldiGTherapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study GroupAging (Milano)20001211210746426
   PubMedGoogle Scholar
• BrownJPKendlerDLMcClungMRThe efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosisCalcif Tissue Int200271210311112085156
   PubMed Web of Science ®Google Scholar
• CooperCEmkeyRDMcDonaldRHEfficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosisJ Clin Endocrinol Metab200388104609461514557430
   PubMed Web of Science ®Google Scholar
• ReginsterJYAdamiSLakatosPEfficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE studyAnn Rheum Dis200665565466116339289
   PubMed Web of Science ®Google Scholar
• DelmasPDBenhamouCLManZMonthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety resultsOsteoporos Int20081971039104518087660
   PubMed Web of Science ®Google Scholar
• DelmasPDMcClungMRZanchettaJREfficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisBone2008421364217920005
   PubMed Web of Science ®Google Scholar
• DelmasPDAdamiSStrugalaCIntravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration studyArthritis Rheum20065461838184616729277
   PubMed Web of Science ®Google Scholar
• SunyeczJOptimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerationsClin Interv Aging20083461162719281054
   PubMed Web of Science ®Google Scholar
• CramerJAGoldDTSilvermanSLLewieckiEMA systematic review of persistence and compliance with bisphosphonates for osteoporosisOsteoporos Int20071881023103117308956
   PubMed Web of Science ®Google Scholar
• SorensenOHCrawfordGMMulderHLong-term efficacy of risedronate: a 5-year placebo-controlled clinical experienceBone200332212012612633783
   PubMed Web of Science ®Google Scholar
• DoggrellSAClinical efficacy and safety of zoledronic acid in prostate and breast cancerExpert Rev Anticancer Ther2009991211121819761424
   PubMed Web of Science ®Google Scholar